Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: Antitumour supra-additive effects on human head and neck cancer xenografts

British Journal of Cancer

Volumn 97, Issue 1, 2007, Pages 65-72

  Bozec, A ^a   Formento, P ^a   Lassalle, S ^b   Lippens, C ^a   Hofman, P ^b   Milano, G ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

Antiangiogenic; AZD2171; Gefitinib; Head and neck cancer; Radiotherapy; Tyrosine kinase inhibitor

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GRAFT; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DNA REPAIR; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; ENDOTHELIUM CELL; GENE EXPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOCYTOCHEMISTRY; MALE; MONOTHERAPY; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREATMENT DURATION; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34347333556     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603791     Document Type: Article

References (26)

1. Bozec A, Formento P, Ciccolini J, Fanciullino R, Padovani L, Murraciole X, Fischel JL, Milano G (2005) Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation. Mol Cancer Ther 4: 1962-1971
2. Cao C, Albert JM, Geng L, Ivy PS, Sandler A, Johnson DH, Lu B (2006) Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer. Cancer Res 66: 11409-11415
3. Ciardiello F, Bianco R, Damiano V, Fontanini G, Caputo R, Pomatico G, De Placido S, Bianco AR, Mendelsohn J, Tortora G (2000) Anti-angiogenic and antitumour activity of antiepidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotides in human GEO colon cancer cells. Clin Cancer Res 6: 3739-3747
4. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR, Tortora G (2001) Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7: 1459-1465
5. Dassonville O, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M, Demard F, Milano G (1993) Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 11: 1873-1878
6. Faivre S, Delbado C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E (2006a) Safety, pharmacokinetic and antitumor activity of SI11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24: 25-35
7. Faivre S, Kroemer G, Raymond E (2006b) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5: 671-688
8. Goswami A, Ranganathan P, Rangnekar V (2006) The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target. Cancer Res 66: 2889-2892
9. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein Jr G, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A (2005) Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23: 2544-2555
10. Herbst RS, Mininberg E, Henderson T, Kim E, Hong WK, Mass R, Novotny W, Garcia B, Johnson D, Sandler A (2003) Phase I/II trial evaluating blockade of tumour blood supply and tumour cell proliferation with combined bevacizumab and erlotinib HCI as targeted cancer therapy in patients with recurrent non-small cell lung cancer. Eur J Cancer 1: S293
11. Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, Kuwano M, Ono M (2002) ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 62: 2554-2560
12. Jain RK, Duda DG, Clark JW, Loeffler JS (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3: 24-40
13. Jung YD, Mansfield PF, Akagi M, Takeda A, Liu W, Bucana CD, Hicklin DJ, Ellis LM (2002) Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 38: 1133-1140
14. Le QT, Giaccia AJ (2003) Therapeutic exploitation of the physiological and molecular genetic alterations in head-and-neck cancer. Clin Cancer Res 9: 4287-4295
15. Nieder C, Wiedenmann N, Andratschke N, Molls M (2006) Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat Rev 32: 348-364
16. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, Radinsky R, Dinney CP (1999) Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 2: 257-265
17. Prewett MC, Hooper AT, Bassi R (2002) Enhanced antitumour activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumour xenografts. Clin Cancer Res 8: 994-1003
18. Raben D, Bianco C, Damiano V, Bianco R, Melisi D, Mignogna C, D'Armiento FP, Cionini L, Bianco AR, Tortora G, Ciardiello F, Bunn P (2004) Antitumour activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD183, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. Mol Cancer Ther 3: 977-983
19. Simon R, Mirlacher M, Sauter G (2004) Tissue microarrays. Biotechniques 36: 98-105
20. Smolewski P (2006) Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 17:487-494
21. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501
22. Wachsberger PR, Burd R, Marero N, Daskalakis C, Ryan A, McCue P, Dicker AP (2005) Effect of the tumour vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 11: 835-842
23. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jürgensmeier JM, Ogilvie DJ (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65: 4389-4400
24. Williams KJ, Telfer BA, Shannon AM, Babur M, Stratford IJ, Wedge SR (2007) Combining radiotherapy with AZD2171, a potent inhibitor, of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit. Mol Cancer Ther 6: 599-606
25. Woodburn JR (1999) The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82: 241-250
26. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J (1998) United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 77: 1-10